RCS - Faron Pharma. Oy - Targeting Soluble Clever-1 for Autoimmune Diseases

Faron Pharmaceuticals OyAnnouncement

11/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK6450La&default-theme=true

RNS Number : 6450L  Faron Pharmaceuticals Oy  11 November 2024

Faron Pharmaceuticals Ltd.

 

("Faron" or "the Company")

 

 Pipeline Update: Targeting Soluble Clever-1 for Autoimmune Diseases

 

Press release, 11 November 2024

 

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North:
FARON), a clinical-stage biopharmaceutical company focused on tackling
cancers and inflammation via novel immunotherapies, today announces the filing
of a patent application around the use of soluble Clever-1 for inactivating
T-cells and the treatment of autoimmune diseases and inflammatory disorders.
The related manuscript can be read here
https://www.biorxiv.org/content/10.1101/2024.10.23.619796v1
(https://www.biorxiv.org/content/10.1101/2024.10.23.619796v1) , which explains
how soluble Clever-1 inactivates T-cells and makes anti-PD-1 based therapies
ineffective in cancer. The key highlights of these findings are the following:

 

•     Clever-1-positive macrophages and endothelial cells secrete a
soluble form of Clever-1;

•     Soluble Clever-1 binds activated T-cells and impairs their
differentiation into anti-tumor effectors;

•     The Company and its researchers have identified the part of
Clever-1 that binds to T-cells and inactivates them; and

•     The submitted patent application covers use of soluble Clever-1 or
fragments of it to inactivate T-cells for the treatment of autoimmune diseases
and inflammatory disorders.

 

The next phase for the Company is to take the identified part of soluble
Clever-1 and design the optimal drug composition with the desired
characteristics for treating autoimmune diseases. The Company will in due
course elucidate this new addition to its pipeline in more detail to expand
the pipeline beyond hematological cancers and solid tumor oncology.

 

"Clever-1 is a master regulator of the immune system. Through decades of
pivotal research and our deep understanding of Clever-1 and its role in human
biology we have now shown how it inactivates T-cells, drives immune tolerance,
and may render anti-PD-1 based immune checkpoint therapies ineffective. In
addition, we now have an understanding on how we can use this to our advantage
in the treatment of unwanted inflammation where T-cells need to be
inactivated. This lays the basis for a new class of drugs to treat
autoinflammatory diseases", says Dr. Maija Hollmén CSO of Faron
Pharmaceuticals.

 

 

For more information please contact:

ICR Healthcare
Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@icrhealthcare.com (mailto:faron@icrhealthcare.com)

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

 

About Faron Pharmaceuticals Ltd

 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell function.
Bexmarilimab is being investigated in Phase I/II clinical trials as a
potential therapy for patients with hematological cancers in combination with
other standard treatments. Further information is available at www.faron.com
(http://www.faron.com) .

 

Forward-Looking Statements

 

Certain statements in this announcement are, or may be deemed to be,
forward-looking statements. Forward looking statements are identified by their
use of terms and phrases such as ''believe'', ''could'', "should", "expect",
"hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'',
''potentially'', ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions. These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the
results and expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition, other factors which
could cause actual results to differ materially include the ability of the
Company to successfully license its programs within the anticipated timeframe
or at all, risks associated with vulnerability to general economic and
business conditions, competition, environmental and other regulatory changes,
actions by governmental authorities, the availability of capital markets or
other sources of funding, reliance on key personnel, uninsured and
underinsured losses and other factors. Although any forward-looking statements
contained in this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that actual
results will be consistent with such forward-looking statements. Accordingly,
readers are cautioned not to place undue reliance on forward-looking
statements. Subject to any continuing obligations under applicable law or any
relevant AIM Rule requirements, in providing this information the Company does
not undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events, conditions or
circumstances on which any such statement is based.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADGBDBGUBDGSG